Pharma Equity Group AS (OCSE:PEG) EBIT per Share: kr-0.02 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Pharma Equity Group AS EBIT per Share?

Pharma Equity Group AS OCSE:PEG -1.45% EBIT per Share is kr-0.02 as of Dec. 2025. The stock has 3 warning signs investors should review. Among 1,173 Biotechnology companies, Pharma Equity Group AS ranks worse than 87.21% on this metric.

Pharma Equity Group AS's EBIT per Share for the six months ended in Dec. 2025 was kr-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was kr-0.02.

During the past 3 years, the average EBIT per Share Growth Rate was -20.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Pharma Equity Group AS's EBIT per Share or its related term are showing as below:

OCSE:PEG' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -62.7   Med: 21   Max: 69.9
Current: -20.5

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Pharma Equity Group AS was 69.90% per year. The lowest was -62.70% per year. And the median was 21.00% per year.

OCSE:PEG's 3-Year EBIT Growth Rate is ranked worse than
87.21% of 1173 companies
in the Biotechnology industry
Industry Median: 15.5 vs OCSE:PEG: -20.50

Pharma Equity Group AS's EBIT for the six months ended in Dec. 2025 was kr-15.30 Mil.

Pharma Equity Group AS  (OCSE:PEG) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Pharma Equity Group AS EBIT per Share Related Terms

Pharma Equity Group AS EBIT per Share Historical Data

* Premium members only.

The historical data trend for Pharma Equity Group AS's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Equity Group AS EBIT per Share Chart

Pharma Equity Group AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 -0.01 -0.02 -0.04 -0.02

Pharma Equity Group AS Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.01 -0.02 -0.01 -0.01

Pharma Equity Group AS EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Pharma Equity Group AS's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-23.863/1227.541
=-0.02

Pharma Equity Group AS's EBIT per Share for the quarter that ended in Dec. 2025 is calculated as

EBIT per Share(Q: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-15.304/1432.133
=-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of kr-0.02 mean?
Pharma Equity Group AS (OCSE:PEG) has a EBIT per Share of kr-0.02 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Pharma Equity Group AS and its competitors. According to the industry distribution chart, Pharma Equity Group AS ranks #1023 out of 1173 companies in the Biotechnology industry, placing it in the top 87.2%.
Is Pharma Equity Group AS's EBIT per Share too high?
Pharma Equity Group AS's current EBIT per Share is kr-0.02. Based on the distribution chart, Pharma Equity Group AS ranks #1023 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Pharma Equity Group AS's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Equity Group AS ranks #1023 out of 1173 companies for EBIT per Share. This places Pharma Equity Group AS in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Pharma Equity Group AS and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Equity Group AS's current EBIT per Share is kr-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Equity Group AS stock overvalued right now?
Pharma Equity Group AS (OCSE:PEG) has a current EBIT per Share of kr-0.02. The current EBIT per Share is kr-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Pharma Equity Group AS (OCSE:PEG), the current EBIT per Share is kr-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharma Equity Group AS Business Description

Address Slotsmarken 12, 1.th, Horsholm, DNK, DK-2970
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .